Amicus Therapeutics, Inc. AM6.F Stock
Amicus Therapeutics, Inc. Price Chart
Amicus Therapeutics, Inc. AM6.F Financial and Trading Overview
Amicus Therapeutics, Inc. stock price | 9.8 EUR |
Previous Close | 12.2 EUR |
Open | 11.7 EUR |
Bid | 11.8 EUR x 50000 |
Ask | 11.9 EUR x 50000 |
Day's Range | 11.7 - 11.7 EUR |
52 Week Range | 7.9 - 12.6 EUR |
Volume | 97 EUR |
Avg. Volume | 0 EUR |
Market Cap | 3.47B EUR |
Beta (5Y Monthly) | 0.797183 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.46 EUR |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 16.9 EUR |
AM6.F Valuation Measures
Enterprise Value | 3.57B EUR |
Trailing P/E | N/A |
Forward P/E | -22.941177 |
PEG Ratio (5 yr expected) | 14.44 |
Price/Sales (ttm) | 10.302482 |
Price/Book (mrq) | 32.320442 |
Enterprise Value/Revenue | 10.604 |
Enterprise Value/EBITDA | -21.422 |
Trading Information
Amicus Therapeutics, Inc. Stock Price History
Beta (5Y Monthly) | 0.797183 |
52-Week Change | 51.99% |
S&P500 52-Week Change | 20.43% |
52 Week High | 12.6 EUR |
52 Week Low | 7.9 EUR |
50-Day Moving Average | 10.56 EUR |
200-Day Moving Average | 10.97 EUR |
AM6.F Share Statistics
Avg. Volume (3 month) | 0 EUR |
Avg. Daily Volume (10-Days) | 0 EUR |
Shares Outstanding | 284.58M |
Float | 208.4M |
Short Ratio | N/A |
% Held by Insiders | 0.86% |
% Held by Institutions | 105.76% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | -60.64% |
Operating Margin (ttm) | -51.041% |
Gross Margin | 88.72% |
EBITDA Margin | -49.50% |
Management Effectiveness
Return on Assets (ttm) | -14.066% |
Return on Equity (ttm) | -119.72% |
Income Statement
Revenue (ttm) | 336.79M EUR |
Revenue Per Share (ttm) | 1.16 EUR |
Quarterly Revenue Growth (yoy) | 9.59% |
Gross Profit (ttm) | 290.63M EUR |
EBITDA | -166712000 EUR |
Net Income Avi to Common (ttm) | -204240000 EUR |
Diluted EPS (ttm) | -0.65 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 267.11M EUR |
Total Cash Per Share (mrq) | 0.94 EUR |
Total Debt (mrq) | 452.01M EUR |
Total Debt/Equity (mrq) | 440.67 EUR |
Current Ratio (mrq) | 2.888 |
Book Value Per Share (mrq) | 0.362 |
Cash Flow Statement
Operating Cash Flow (ttm) | -126329000 EUR |
Levered Free Cash Flow (ttm) | -66124500 EUR |
Profile of Amicus Therapeutics, Inc.
Country | Germany |
State | PA |
City | Philadelphia |
Address | 3675 Market Street |
ZIP | 19104 |
Phone | 215 921 7600 |
Website | https://amicusrx.com |
Industry | Biotechnology |
Sector(s) | Healthcare |
Full Time Employees | 484 |
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data. The company also develops AT-GAA, a novel treatment paradigm for Pompe disease; and enzyme replacement therapies for Pompe diseases. It has collaboration and license agreements with Nationwide Children's Hospital; University of Pennsylvania; and GlaxoSmithKline. The company was incorporated in 2002 and is headquartered in Philadelphia, Pennsylvania.
Q&A For Amicus Therapeutics, Inc. Stock
What is a current AM6.F stock price?
Amicus Therapeutics, Inc. AM6.F stock price today per share is 9.8 EUR.
How to purchase Amicus Therapeutics, Inc. stock?
You can buy AM6.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Amicus Therapeutics, Inc.?
The stock symbol or ticker of Amicus Therapeutics, Inc. is AM6.F.
Which industry does the Amicus Therapeutics, Inc. company belong to?
The Amicus Therapeutics, Inc. industry is Biotechnology.
How many shares does Amicus Therapeutics, Inc. have in circulation?
The max supply of Amicus Therapeutics, Inc. shares is 296.2M.
What is Amicus Therapeutics, Inc. Price to Earnings Ratio (PE Ratio)?
Amicus Therapeutics, Inc. PE Ratio is now.
What was Amicus Therapeutics, Inc. earnings per share over the trailing 12 months (TTM)?
Amicus Therapeutics, Inc. EPS is -0.46 EUR over the trailing 12 months.
Which sector does the Amicus Therapeutics, Inc. company belong to?
The Amicus Therapeutics, Inc. sector is Healthcare.